Stockhub

Phio Pharmaceuticals Corp.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

13 August 2022

30 July 2022

  • curprev 19:4419:44, 30 July 2022 172.18.0.2 talk 1,033 bytes +1,033 Created page with "Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an i..."
Retrieved from "https://stockhub.co/research/Phio_Pharmaceuticals_Corp."